• 1
    Dowson AJ, Shapero G, Baos V et al. Primary care needs assessment for guidance on headache management. Headache Care 2005; 2: 436.
  • 2
    Kern R, Shapero G, Boudreau G et al. There is a strong unmet need for improved headache education among primary care physicians: results from a primary care needs assessment. Headache Care 2005; 2: 479.
  • 3
    International Headache Society. Headache classification subcommittee. Cephalalgia 1988; 8 (Suppl. 7): S196.
  • 4
    Lipton RB, Diamond S, Reed M et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 63845.
  • 5
    MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 2003; 43: 1926.
  • 6
    Edmeads J, Lainez JM, Brandes JL et al. Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology 2001; 56 (6 Suppl. 1): S2934.
  • 7
    MacGregor EA, Brandes J, Gendolla A, Giammarco R. Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey – phase IV. Curr Med Res Opin 2004; 20: 177783.
  • 8
    Gawel MJ, Worthington I, Maggisano A. Systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001; 28: 3041.
  • 9
    Gibbs TS, Fleischer AB Jr, Feldman SR et al. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache 2003; 43: 3305.
  • 10
    MacGregor EA. The doctor and the migraine patient: improving compliance. Neurology 1997; 48 (Suppl. 3): S1620.
  • 11
    Dowson AJ, Tepper SJ, Dahlöf C. Patients’ preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain 2005; 6: 11220.
  • 12
    Tfelt-Hansen P, Block G, Dahlöf C et al. International Headache Society clinical trials subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 76586.
  • 13
    Almqvist P, Brandreth T. ZAP primary care programme: headache education through clinical experience. Headache Care 2005; 2: 23942.
  • 14
    Dowson AJ, MacGregor EA, Purdy RA et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002; 22: 1016.
  • 15
    Spierings ELH, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 2004; 18: 113341.
  • 16
    Loder EW, Dowson AJ, Spierings EL. Part II: clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. Curr Med Res Opin 2005; 21 (Suppl. 3): S812.